Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated, commercial-stage biopharmaceutical company, announced the promotion of Thomas Englese to chief commercial officer, effective immediately. Englese, who previously served as executive vice president of commercial operations since September 2024, will now oversee all sales, marketing, market access, and commercial operations for TONMYA, the company's treatment for fibromyalgia in adults, as well as its acute migraine products Zembrace SymTouch and Tosymra.
The promotion comes at a critical time as Tonix works to expand the commercial footprint of TONMYA, which was approved by the U.S. Food and Drug Administration and launched recently. Seth Lederman, president and CEO of Tonix, emphasized Englese's instrumental role in building the company's commercial organization and executing the launch of TONMYA. "Tom has been instrumental in building the Tonix commercial organization and launching TONMYA," Lederman said in a press release. "His leadership and deep expertise in the CNS space will be vital as we work to bring this important treatment to more patients suffering from fibromyalgia."
Englese expressed his commitment to the company's mission, stating, "We are focused on expanding access, growing our patient and prescriber base, and increasing sales as we broaden the TONMYA launch. I look forward to continuing to work with the talented team at Tonix to ensure that patients have access to this innovative therapy."
The significance of this appointment lies in Tonix's strategic focus on commercializing TONMYA, which is the first new treatment for fibromyalgia in more than 15 years. Fibromyalgia is a chronic condition characterized by widespread pain, fatigue, and cognitive difficulties, affecting an estimated 4 million adults in the United States. The market potential for TONMYA is substantial, and Tonix's commercial success will depend on effective market access, physician education, and patient awareness.
Tonix's CNS portfolio also includes Zembrace SymTouch and Tosymra for acute migraine, which are already marketed. The company continues to invest in research and development, with ongoing Phase 2 clinical trials evaluating TONMYA's potential in major depressive disorder and acute stress disorder. Additionally, Tonix is developing TNX-2900 for Prader-Willi syndrome and advancing immunology programs, including TNX-4800 for Lyme disease prophylaxis and TNX-1500 for prevention of kidney transplant rejection.
The promotion of Englese to chief commercial officer signals Tonix's dedication to building a robust commercial infrastructure to maximize the market potential of its products. As the company expands the launch of TONMYA, the experience and leadership of Englese will be crucial in driving sales growth and establishing a strong presence in the CNS therapeutic area.
Investors should note that Tonix's product development candidates are investigational and have not been approved for any indication, and their efficacy and safety have not been established. The company's newsroom provides the latest updates and information about its pipeline and commercial activities.
